Hospital
Our Lady of the Angels Hospital, INC.
Our Lady of the Angels Hospital, INC. was paid $16.10M by Medicaid between Jan 2018 and Dec 2024, across 198 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoOUR LADY OF THE ANGELS HOSPITAL, INC.
BOGALUSA, LA 70427
BOGALUSA, LA 70427
33aNPI1093140600assigned 09/13/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.10M
24GClaims496,567
24DCodes billed198
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#28 of 96
Median peer was paid$5.17M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,371 | $1.69M | |
| 2019 | 68,247 | $1.87M | |
| 2020 | 49,534 | $1.38M | |
| 2021 | 68,346 | $2.51M | |
| 2022 | 85,077 | $3.19M | |
| 2023 | 91,853 | $3.20M | |
| 2024incomplete | 65,139 | $2.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 35,133 | 32,181 | $3.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 13,177 | 12,001 | $2.06M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.3% | 39,992 | 33,869 | $1.33M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 8.1% | 47,725 | 40,528 | $1.30M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.2% | 4,339 | 3,805 | $832K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.0% | 15,944 | 14,213 | $801K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.6% | 2,882 | 2,234 | $582K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 6,960 | 6,486 | $506K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 12,038 | 10,806 | $440K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 1,263 | 1,141 | $354K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.9% | 23,427 | 11,652 | $309K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 5,956 | 5,267 | $295K |
186 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.7% | 10,389 | $270K |
| 45384 | 1.6% | 1,586 | $254K | |
| 20610 | 1.6% | 1,131 | $252K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 10,653 | $220K |
| 80053 | Comprehensive metabolic panel | 1.3% | 30,355 | $210K |
| G0378 | Hospital observation service, per hour | 1.3% | 583 | $206K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 8,630 | $185K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 5,126 | $181K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 359 | $175K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 559 | $166K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,691 | $158K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,860 | $118K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,609 | $102K |
| 36415 | Collection of venous blood by venipuncture | <1% | 42,476 | $78K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 446 | $77K |
| 92551 | <1% | 508 | $57K | |
| 73630 | <1% | 610 | $44K | |
| 84484 | <1% | 6,449 | $40K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 950 | $39K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,218 | $39K |
| 81025 | <1% | 5,956 | $38K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 91 | $37K |
| 94060 | <1% | 315 | $35K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,704 | $35K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 606 | $34K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 76 | $27K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 703 | $24K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 745 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 744 | $23K |
| 81001 | <1% | 11,389 | $23K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 931 | $23K |
| 90686 | <1% | 1,108 | $22K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 53 | $21K |
| 73562 | <1% | 255 | $21K | |
| 80061 | Lipid panel | <1% | 1,904 | $21K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,729 | $21K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 744 | $19K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 108 | $19K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,063 | $17K |
| 81003 | <1% | 7,772 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,445 | $15K |
| 87070 | <1% | 2,150 | $13K | |
| 31231 | <1% | 25 | $12K | |
| 94729 | <1% | 258 | $11K | |
| 87807 | <1% | 1,024 | $11K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 53 | $11K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 994 | $11K |
| 83735 | <1% | 2,779 | $10K | |
| 87522 | Neg quan hep c or qual rna | <1% | 273 | $10K |
| 83690 | <1% | 2,143 | $10K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 79 | $9K |
| 93017 | <1% | 132 | $9K | |
| 90682 | <1% | 174 | $9K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 217 | $8K |
| 94727 | <1% | 189 | $8K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 19 | $8K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 144 | $8K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 139 | $8K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,366 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,997 | $7K |
| 87040 | <1% | 756 | $6K | |
| 83880 | <1% | 339 | $5K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 704 | $5K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 348 | $5K |
| 80050 | General health panel | <1% | 113 | $5K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 184 | $4K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 358 | $3K |
| 52000 | <1% | 13 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 46 | $3K |
| G0127 | Trimming of dystrophic nails, any number | <1% | 222 | $3K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 179 | $3K |
| 96376 | <1% | 96 | $3K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 52 | $3K |
| 73030 | <1% | 43 | $3K | |
| 81002 | <1% | 1,079 | $3K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 15 | $3K |
| 97802 | <1% | 135 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 723 | $3K |
| 93925 | <1% | 33 | $3K | |
| 99173 | <1% | 438 | $2K | |
| 11719 | <1% | 120 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 72 | $2K |
| 87536 | <1% | 40 | $2K | |
| 85610 | <1% | 933 | $2K | |
| 73130 | <1% | 50 | $2K | |
| 88142 | <1% | 220 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 34 | $2K |
| 85730 | <1% | 688 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12,344 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 54 | $2K |
| 80076 | <1% | 293 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 336 | $2K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 114 | $2K |
| 87081 | <1% | 259 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 552 | $2K |
| 83605 | <1% | 255 | $2K | |
| 94664 | <1% | 170 | $1K | |
| 82962 | <1% | 867 | $1K | |
| 72170 | <1% | 25 | $1K | |
| 86360 | <1% | 38 | $1K | |
| 82105 | <1% | 104 | $1K | |
| 83655 | <1% | 140 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,835 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 54 | $1K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 14 | $1K |
| 86359 | <1% | 39 | $1K | |
| 82077 | <1% | 163 | $1K | |
| 96160 | <1% | 85 | $1K | |
| 87428 | <1% | 61 | $1K | |
| 43450 | <1% | 1,875 | $1K | |
| 82570 | <1% | 261 | $1K | |
| 0001A | <1% | 494 | $1K | |
| 82043 | <1% | 215 | $1K | |
| 93041 | <1% | 101 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 2,514 | $998.37 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 557 | $834.79 |
| 92134 | <1% | 60 | $802.78 | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,081 | $782.28 |
| 84439 | <1% | 88 | $718.68 | |
| 85018 | <1% | 317 | $706.11 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 78 | $696.75 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,999 | $689.79 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 52 | $683.85 |
| 90715 | <1% | 14 | $614.22 | |
| 82550 | <1% | 167 | $609.42 | |
| 90461 | <1% | 700 | $602.63 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 26 | $549.75 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 944 | $525.18 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 18 | $481.27 |
| 90670 | <1% | 247 | $418.32 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $397.97 |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 15 | $394.19 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 13 | $389.90 |
| 92083 | <1% | 13 | $372.42 | |
| 87186 | <1% | 75 | $328.70 | |
| 85379 | <1% | 49 | $315.58 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 127 | $312.10 |
| 84550 | <1% | 76 | $311.03 | |
| 84100 | <1% | 149 | $306.75 | |
| 87340 | <1% | 26 | $298.88 | |
| 90673 | <1% | 399 | $284.16 | |
| 99201 | <1% | 12 | $258.88 | |
| 84481 | <1% | 26 | $237.09 | |
| 92133 | <1% | 13 | $236.32 | |
| 87077 | <1% | 45 | $234.32 | |
| 93922 | <1% | 18 | $232.78 | |
| 85652 | <1% | 92 | $217.44 | |
| 82150 | <1% | 52 | $200.88 | |
| 86704 | <1% | 12 | $174.72 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 45 | $168.53 |
| 92015 | Determination of refractive state | <1% | 29 | $153.60 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,748 | $145.04 |
| 86592 | <1% | 39 | $143.62 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 25 | $140.98 |
| 86140 | <1% | 25 | $133.40 | |
| 87210 | <1% | 47 | $115.82 | |
| 90671 | <1% | 625 | $106.98 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 44 | $106.26 |
| 90681 | <1% | 115 | $103.93 | |
| 90698 | <1% | 117 | $101.59 | |
| 36416 | <1% | 107 | $90.10 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 81 | $88.21 |
| 86850 | <1% | 17 | $80.88 | |
| 86431 | <1% | 12 | $68.75 | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,239 | $47.08 |
| 86900 | <1% | 17 | $35.88 | |
| 86901 | <1% | 17 | $35.88 | |
| 82270 | <1% | 12 | $33.72 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 14 | $28.60 |
| 90633 | <1% | 187 | $22.77 | |
| G0009 | Administration of pneumococcal vaccine | <1% | 44 | $21.09 |
| 90474 | <1% | 23 | $5.02 | |
| 88312 | 0% | 247 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 290 | $0.00 |
| 90685 | 0% | 56 | $0.00 | |
| 0002A | 0% | 60 | $0.00 | |
| 80320 | 0% | 36 | $0.00 | |
| 88342 | 0% | 713 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 392 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 2,205 | $0.00 |
| 90677 | 0% | 26 | $0.00 | |
| 90680 | 0% | 132 | $0.00 | |
| 90697 | 0% | 138 | $0.00 | |
| 90656 | 0% | 128 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSPICER, CHUCK (MARKET PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Our Lady of the Lake Hospital INC. | Baton Rouge, LA | $205.69M |
| Our Lady of the Angels Hospital, INC. | Bogalusa, LA | $8.94M |
| Our Lady of the Angels Clinic | Bogalusa, LA | $10K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.